Key result
Major cardiovascular events-GPS tests early capsule endoscopy vs conventional care for GI bleeding in high-bleeding-risk PCI.
Why the study?
Data are limited regarding decision-making to prevent gastrointestinal bleeding in patients at high bleeding risk scheduled for PCI, partly due to lacking simple, accurate, and sensitive detection methods.
Does early magnetically controlled capsule endoscopy prevent gastrointestinal bleeding in patients at high bleeding risk scheduled for percutaneous coronary intervention?
RCT (n=2,456)
Open-label
randomized
Yes
Does early magnetically controlled capsule endoscopy prevent gastrointestinal bleeding in patients at high bleeding risk scheduled for percutaneous coronary intervention?
Answers are grounded in this paper and cite their sources.
This study protocol describes a randomized trial to evaluate whether early magnetically controlled capsule endoscopy reduces gastrointestinal bleeding in high-bleeding-risk patients undergoing PCI.
INTRODUCTION: Limited data are available regarding the decision-making process for preventing gastrointestinal bleeding in patients at high risk of bleeding scheduled for percutaneous coronary intervention (HBPCI), especially due to the lack of a simple, accurate and sensitive methods for gastrointestinal injury detection. This randomised trial aims to assess the effects of early magnetically controlled capsule endoscopy (MCE) in patients with HBPCI for the prevention of gastrointestinal bleeding compared with conventional management. METHODS AND ANALYSIS: The Magnetic-Assisted Capsule Endoscopy Gastrointestinal bleeding Protection Strategy (MACE-GPS) is a multicentre, open-label, randomised controlled trial. Patients admitted for HBPCI will be randomised and placed into two study groups. In the early MCE group, 1228 patients will undergo MCE following admission to the hospital. If necessary, these patients may further undergo a multidisciplinary approach to determine treatment based on the MCE findings. A total of 1228 patients in the control group will undergo conventional treatment based on the attending cardiologist's interpretation of their clinical presentations. The primary end point is the incidence of gastrointestinal bleeding within 12 months of enrolment. ETHICS AND DISSEMINATION: The MACE-GPS trial has been approved by the ethics committees of all participating sites. Participant recruitment began in April 2023 and will be completed in April 2025, and the 1-year follow-up will be completed in April 2026. The study results will be disseminated through conference presentations and peer-reviewed publications. TRIAL REGISTRATION NUMBER: ChiCTR2300070025.
No takes yet. Share an insight, caveat, or question.
Li et al. (2024) conducted an RCT in High bleeding risk scheduled for percutaneous coronary intervention (HBPCI) (n=2,456). Early magnetically controlled capsule endoscopy (MCE) vs. Conventional management was evaluated on Incidence of gastrointestinal bleeding within 12 months of enrolment. The major cardiovascular events-GPS trial will randomize 2456 patients at high bleeding risk scheduled for PCI to early magnetically controlled capsule endoscopy or conventional management to assess GI bleeding incidence.
Synapse has enriched 10 related papers. Consider them for comparative context: